Morocco
Present in Morocco since 2015, Cipla's added value to the Moroccan healthcare landscape was quickly noticeable, by the inauguration of the country's first inhalers manufacturing unit, responding to the need of millions of Moroccans to respiratory products access.
Cipla Morocco current focus is made on two therapeutic segments. Respiratory products covering asthma, COPD and allergic rhinitis, and CNS products treating depression, schizophrenia and bipolar disoder. With an important pipeline of products that are under registration, Cipla Morocco aims to enrich healthcare professionals therapeutic arsenal, and mainly, promote access to as many people as possible to high quality products, regardless of where they live or how much they earn.
Quick Facts
Commenced Operations
2015
Employees
75
Turnover
$23Mn
CEO - Cipla South Africa
Paul Miller
Deputy Head of One Africa
Mark Daly
Country Head
Mohamed Janah
sis au 62 Route El Jadida – Casablanca
To report a product complaint, adverse drug event, please email to drugsafety@cipla.com
Cipla has a long heritage of being a world leader in Respiratory Therapy - India, South Africa and various Emerging Markets to name a few. In keeping with our purpose of ‘Caring for Life’, we are constantly working towards improving patient access to necessary and innovative medicines for better management of diseases and improved quality of life. We pride ourselves in having the world’s largest respiratory range of drugs, dosage forms and devices for COPD and Asthma. Our products are available in more than 80+ countries worldwide. Key products were successfully launched in many European countries e.g. UK, Germany, Belgium, Netherlands, Czech Republic and Croatia.
